Medtronic unveils infusion set for diabetes in Europe

27 April 2021


Infusion

Medtronic has unveiled its Extended infusion set, the first set that can be worn to deliver insulin for up to seven days, in select European countries.

Infusion sets are tubing that provides insulin to the body from a pump, and they usually need to be changed every few days.

The Extended infusion set doubles the time a set can be worn. It allows users to safely stay on insulin pump therapy with fewer interruptions and insertions while also providing improved convenience and comfort for patients’ diabetes management routine.

As part of a patient evaluation programme, more than 100 insulin pump users in Finland trialled the Extended infusion set, and Medtronic received positive feedback from them on their experience.

Developed in collaboration with ConvaTec’s Unomedical subsidiary, the set can be used with all MiniMed 600 and 700 series insulin pumps.

Its new design uses advanced materials to reduce insulin preservative loss and preserve the flow and stability of insulin.

Furthermore, the new tubing connector enhances insulin’s physical and chemical stability and the reliability of infusion site performance. It also cuts down the risk of infusion set occlusion.

The adhesive patch has an adhesive layer that provides prolonged wear time, as well as comfort and durability for up to seven days.

Medtronic Diabetes Business customer experience vice-president Julie Foster said: “Our goal with this latest innovation is to make insulin pump therapy easier for people living with diabetes.

“The Medtronic Extended infusion set introduces increased simplicity and convenience — something we’re looking to deliver across all of our products and services to help ease burden and enhance the experience for people wherever they are in their diabetes journey.”

The infusion set is commercially available in select European countries, including Finland and Belgium, and will be made available to other countries in a phased approach over the year.

Last month, Medtronic received the CE Mark for its SenSight directional lead system for deep brain stimulation therapy to treat symptoms linked to movement disorders and epilepsy.

You’ve read about the new infusion set to provide improved convenience and comfort for patients’ diabetes management routine. Would you like to contribute to the development of innovative solutions for diabetes technology? Check out our vacancies!


Published on Medicaldevice-network.com